Results 161 to 170 of about 455,442 (295)

Prime editing in neuropsychiatric disorders: From mutation‐specific target selection to clinical translation

open access: yesNeuroprotection, EarlyView.
Abstract Prime editing, a novel clustered regularly interspaced short palindromic repeats (CRISPR)‐based technology, fuses a reverse transcriptase (RT) to an engineered CRISPR‐associated protein 9 (Cas9) and uses a prime editing guide RNA (pegRNA)‐encoded template.
Tianshan Ji   +4 more
wiley   +1 more source

Time‐Resolved Effects of Cold Atmospheric Plasma on E. coli GW‐AmxH19 Transcriptome and Proteome in an Emulated Wastewater Environment

open access: yesPROTEOMICS, EarlyView.
ABSTRACT Cold atmospheric plasma (CAP) is effective against a variety of microorganisms. Here, we described effects on an Escherichia coli strain isolated from hospital wastewater caused by treatment with physical plasma. E. coli GW‐AmxH19 was incubated in artificial wastewater and treated for 15 min with CAP.
Jörg Bernhardt   +11 more
wiley   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

open access: yesPrecision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan   +3 more
wiley   +1 more source

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley   +1 more source

Home - About - Disclaimer - Privacy